HLA-A∗ 02 in relation to outcome in human papillomavirus positive tonsillar and base of tongue cancer

Anticancer Research

Volumn 34, Issue 5, 2014, Pages 2369-2376

  Tertipis, Nikolaos ^a   Villabona, Lisa ^a   Nordfors, Cecilia ^a   Näsman, Anders ^a   Ramqvist, Torbjörn ^a   Vlastos, Andrea ^a   Masucci, Giuseppe ^a   Dalianis, Tina ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Base of tongue cancer; Clinical outcome; HLA A 02 genotype; Human papillomavirus (HPV) oropharyngeal squamous cell carcinoma; Tonsillar cancer

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CLINICAL EXAMINATION; DISEASE FREE SURVIVAL; FEMALE; HLA SYSTEM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA; TONSIL CARCINOMA; TONSILLAR SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR VOLUME; UNIVERSITY HOSPITAL; WART VIRUS; BASE OF TONGUE CANCER; BIOSYNTHESIS; CLINICAL OUTCOME; GENETICS; HLA-A*02 GENOTYPE; HUMAN PAPILLOMAVIRUS (HPV) OROPHARYNGEAL SQUAMOUS CELL CARCINOMA; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TONGUE TUMOR; TONSIL CANCER; TONSIL TUMOR; VERY ELDERLY; VIROLOGY;

HLA A*02 ANTIGEN; HLA A2 ANTIGEN; HLA-A*02 ANTIGEN; TUMOR MARKER;

BASE OF TONGUE CANCER; CLINICAL OUTCOME; HLA-A*02 GENOTYPE; HUMAN PAPILLOMAVIRUS (HPV) OROPHARYNGEAL SQUAMOUS CELL CARCINOMA; TONSILLAR CANCER;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HLA-A2 ANTIGEN; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TONGUE NEOPLASMS; TONSILLAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84902960654     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. WHO. IARC Monographs on the Evaluation of carcinogenic risk to humans. Lyon, France: International Agency for Research on Cancer, 2007.
2. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV and Sidransky D: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92: 709-720, 2000.
3. Mellin H, Friesland S, Lewensohn R, Dalianis T and Munck-Wikland E: Human papillomavirus (HPV) DNA in tonsillar cancer: Clinical correlates, risk of relapse, and survival. Int J Cancer 89: 300-304, 2000.
4. Robinson KL and Macfarlane GJ: Oropharyngeal cancer incidence and mortality in Scotland: are rates still increasing? Oral Oncol 39: 31-36, 2003.
5. Hammarstedt L, Lindquist D, Dahlstrand H, Romanitan M, Dahlgren LO, Joneberg J, Creson N, Lindholm J, Ye W, Dalianis T and Munck-Wikland E: Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 119: 2620-2623, 2006.
6. Conway DI, Stockton DL, Warnakulasuriya KA, Ogden G and Macpherson LM: Incidence of oral and oropharyngeal cancer in United Kingdom (1990-1999)-recent trends and regional variation. Oral Oncol 42: 586-592, 2006.
7. Hammarstedt L, Dahlstrand H, Lindquist D, Onelöv L, Ryott M, Luo J, Dalianis T, Ye W and Munck-Wikland E: The incidence of tonsillar cancer in Sweden is increasing. Acta Otolaryngol 127: 988-992, 2007.
8. Sturgis EM and Cinciripini PM: Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-Associated cancers? Cancer 110: 1429-1435, 2007.
9. Romanitan M, Näsman A, Ramqvist T, Dahlstrand H, Polykretis L, Vogiatzis P, Vamvakas P, Tasopoulos G, Valavanis C, Arapantoni-Dadioti P, Banis K and Dalianis T: Human papillomavirus frequency in oral and oropharyngeal cancer in Greece. Anticancer Res 28: 2077-2080, 2008.
10. Näsman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraud G, Sparén P, Ye W, Dahlstrand H, Munck-Wikland E and Dalianis T: Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: An epidemic of viral-induced carcinoma? Int J Cancer 125: 362-366, 2009.
11. Braakhuis BJ, Visser O and Leemans CR: Oral and oropharyngeal cancer in The Netherlands between 1989 and 2006: Increasing incidence, but not in young adults. Oral Oncol 45: e85-89, 2009.
12. Attner P, Du J, Näsman A, Hammarstedt L, Ramqvist T, Lindholm J, Marklund L, Dalianis T and Munck-Wikland E: The role of human papillomavirus in the increased incidence of base of tongue cancer. Int J Cancer 126: 2879-2884, 2010.
13. Marur S, D'Souza G, Westra WH and Forastiere AA: HPV-Associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11: 781-789, 2010.
14. Ramqvist T and Dalianis T: Oropharyngeal epidemic and human papillomavirus. Emerg Infect Dis 16: 1671-1677, 2010.
15. Ramqvist T and Dalianis T: An epidemic of oropharyngeal squamous cell carcinoma (OSCC) due to human papillomavirus (HPV) infection and aspects of treatment and prevention. Anticancer Res 31: 1515-1519, 2011.
16. Mellin H, Dahlgren L, Munck-Wikland E, Lindholm J, Rabbani H, Kalantari M, and Dalianis T: Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int J Cancer 102: 152-158, 2002.
17. Mellin H, Friesland S, Auer G, Dalianis T and Munck-Wikland E: Human papillomavirus and DNA ploidy in tonsillar cancer-correlation to prognosis. Anticancer Res 23: 2821-2828, 2003.
18. Dahlgren L, Mellin H, Wangsa D, Heselmeyer-Haddad K, Björnestål L, Lindholm J, Munck-Wikland E, Auer G, Ried T and Dalianis T: Comparative genomic hybridization analysis of tonsillar cancer reveals a different pattern of genomic imbalances in human papillomavirus-positive and-negative tumors. Int J Cancer 107: 244-249, 2003.
19. Dahlgren L, Dahlstrand HM, Lindquist D, Högmo A, Björnestål L, Lindholm J, Lundberg B, Dalianis T and Munck-Wikland E: Human papillomavirus is more common in base of tongue than in mobile tongue cancer and is a favorable prognostic factor in base of tongue cancer patients. Int J Cancer 112: 1015-1019, 2004.
20. Dahlstrand HM and Dalianis T: Presence and influence of human papillomaviruses (HPV) in tonsillar cancer. Adv Cancer Res 93: 59-89, 2005.
21. Lindquist D, Romanitan M, Hammarstedt L, Nasman A, Dahlstrand H, Lindholm J, Onelöv L, Ramqvist T, Ye W, Munck-Wikland E and Dalianis T: Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7. Mol Oncol 1: 350-355, 2007.
22. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP and Gillison ML: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363: 24-35, 2010.
23. Attner P, Du J, Näsman A, Hammarstedt L, Ramqvist T, Lindholm J, Marklund L, Dalianis T and Munck-Wikland E: Human papillomavirus and survival in patients with base of tongue cancer. Int J Cancer 128: 2892-2897, 2011.
24. Licitra L, Bernier J, Grandi C, Merlano M, Bruzzi P and Lefebvre JL: Cancer of the oropharynx. Crit. Rev Oncol Hematol 41: 107-122, 2002.
25. Näsman A, Andersson E, Nordfors C, Grün N, Johansson H, Munck-Wikland E, Massucci G, Dalianis T and Ramqvist T: MHC class I expression in HPV-positive and-negative tonsillar squamous cell carcinoma in correlation to clinical outcome. Int J Cancer 132: 72-81, 2013.
26. Näsman A, Andersson E, Marklund L, Tertipis N, Hammarstedt-Nordenwall L, Nyberg T, Munck-Wikland E, Masucci GV, Ramqvist T and Dalianis T: HLA class I and II expression in oropharyngeal squamous cell carcinoma in relation to tumor HPV status and clinical outcome. PloS One 8: e7702543, 2013.
27. Lindquist D, Ahrlund-Richter A, Tarján M, Tot T and Dalianis T: Intense CD44 expression is a negative prognostic factor in tonsillar and base of tongue cancer. Anticancer Res 32: 153-161, 2012.
28. Näsman A Nordfors C, Grün N, Munck-Wikland E, Ramqvist T, Marklund L, Lindquist D and Dalianis T: Absent/weak CD44 intensity and positive human papillomavirus (HPV) status in oropharyngeal squamous cell carcinoma indicates a very high survival. Cancer Med 2: 507-518, 2013.
29. Rietbergen MM, Martens-de Kemp SR, Bloemena E, Witte BI, Brink A, Baatenburg de Jong RJ, Leemans CR, Braakhuis BJ and Brakenhoff RH: Cancer stem cell enrichment marker CD98: A prognostic factor for survival in patients with human papillomavirus-positive oropharyngeal cancer. Eur J Cancer 50: 765-773, 2014.
30. Näsman A, Romanitan M, Nordfors C, Grün N, Johansson H, Hammarstedt L, Marklund L, Munck-Wikland E, Dalianis T and Ramqvist T: Tumor infiltrating CD8+ and FOXP3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PLoS One 7: e38711, 2012.
31. Nordfors C, Grün N, Tertipis N, Ahrlund-Richter A, Haeggblom L, Sivars L, Du J, Nyberg T, Marklund L, Munck-Wikland E, Näsman A, Ramqvist T and Dalianis: CD8+ and CD4+ tumour-infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma. Eur J Cancer 9: 2522-2530, 2013.
32. Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. Nature 401: 921-923, 1999.
33. Little AM and Parham P: Polymorphism and evolution of HLA class I and II genes and molecules. Immunogenetics 1: 105-123, 1999.
34. Gamzatova Z, Villabona L, Dahlgren L, Dalianis T, Nillson B, Bergfeldt K and Masucci GV: Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer. Gynecol Oncol 103: 145-150, 2006.
35. Andersson E, Villabona L, Bergfeldt K, Carlson JW, Ferrone S, Kiessling R, Seliger B and Masucci GV: Correlation of HLA-A∗02 genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. Cancer Immunol Immunother 61: 1243-1253, 2012.
36. De Petris L, Bergfeldt K, Hising C, Lundqvist A, Tholander B, Pisa P, van der Zanden HG and Masucci G: Correlation between HLA-A∗02 gene frequency, latitude, ovarian and prostate cancer mortality rates. Med Oncol 21: 49-52, 2004.
37. Helgadottir H, Andersson E, Villabona L, Kanter L, van der Zanden H, Haasnoot GW, Seliger B, Bergfeldt K, Hansson J, Ragnarsson-Olding B, Kiessling R and Masucci GV: The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma. Cancer Immunol Immunother 58: 1599-1608, 2009.
38. Davidson EJ, Davidson JA, Sterling JC, Baldwin PJ, Kitchener HC and Stern PL: Association between human leukocyte antigen polymorphism and human papillomavirus 16-positive vulval intraepithelial neoplasia in British women. Cancer Res 63: 400-403, 2003.
39. Montoya L, Saiz I, Rey G, Vela F and Clerici-Larradet N: Cervical carcinoma: human papillomavirus infection and HLA-Associated risk factors in the Spanish population. Eur J Immunogenet 25: 329-337, 1998.
40. Villabona L, Andersson E, Marchesi M and Masucci GV: Genotyping of human leukocyte antigen (HLA) ancestral haplotypes as prognostic marker in cancer using PCR analysis. Methods Mol Biol 1102: 353-366, 2014.
41. Marklund L, Näsman A, Ramqvist T, Dalianis T, Munck-Wikland E and Hammarstedt L: Prevalence of human papillomavirus and survival in oropharyngeal cancer other than tonsil or base of tongue cancer. Cancer Med 1: 82-88, 2012.